The content on this site is intended for healthcare professionals only
Dr Tsimberidou presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show using molecular tests of tumours to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types.
She describes how, of the 1,307 patients with at least one genetic change in the cancer, the 3-year overall survival rate was 15% in the matched targeted group compared to 7% in the non-matched group.
The 10-year overall survival rate was 6% for the matched group and 1% in the non-matched group.
For more on these results, watch her interview with ecancer here, and read our news coverage here.
Slides from this presentation are available here.
Multiple myeloma In Rwanda: The need for further research
Hormonal receptor positive breast cancer adjuvant and metastatic indications
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC
